连续重新评估及相关剂量探索设计
Continual Reassessment and Related Dose-Finding Designs.
作者信息
O'Quigley John, Conaway Mark
机构信息
Inserm, Université Paris VI, Place Jussieu, 75005 Paris, France.
出版信息
Stat Sci. 2010;25(2):202-216. doi: 10.1214/10-STS332.
Abstract
During the last twenty years there have been considerable methodological developments in the design and analysis of Phase 1, Phase 2 and Phase 1/2 dose-finding studies. Many of these developments are related to the continual reassessment method (CRM), first introduced by O'Quigley, Pepe and Fisher (1990). CRM models have proven themselves to be of practical use and, in this discussion, we investigate the basic approach, some connections to other methods, some generalizations, as well as further applications of the model. We obtain some new results which can provide guidance in practice.
摘要
在过去二十年中，在1期、2期以及1/2期剂量探索研究的设计和分析方面，方法学有了显著发展。其中许多发展都与连续重新评估法（CRM）有关，该方法由奥奎利、佩佩和费舍尔于1990年首次提出。CRM模型已证明自身具有实际用途，在本次讨论中，我们将研究其基本方法、与其他方法的一些联系、一些推广以及该模型的进一步应用。我们获得了一些新结果，可为实践提供指导。
相似文献
1
Continual Reassessment and Related Dose-Finding Designs.连续重新评估及相关剂量探索设计
Stat Sci. 2010;25(2):202-216. doi: 10.1214/10-STS332.
2
The continual reassessment method for dose-finding studies: a tutorial.剂量探索研究的连续重新评估方法：教程
Clin Trials. 2006;3(1):57-71. doi: 10.1191/1740774506cn134oa.
3
Curve-free and model-based continual reassessment method designs.无曲线和基于模型的连续重新评估方法设计。
Biometrics. 2002 Mar;58(1):245-9. doi: 10.1111/j.0006-341x.2002.00245.x.
4
Sensitivity of dose-finding studies to observation errors.剂量探索研究对观测误差的敏感性。
Contemp Clin Trials. 2009 Nov;30(6):523-30. doi: 10.1016/j.cct.2009.06.008. Epub 2009 Jul 4.
5
How to design a dose-finding study using the continual reassessment method.如何使用连续评估法设计剂量探索研究。
BMC Med Res Methodol. 2019 Jan 18;19(1):18. doi: 10.1186/s12874-018-0638-z.
6
Retrospective robustness of the continual reassessment method.连续重新评估法的回顾性稳健性。
J Biopharm Stat. 2010 Sep;20(5):1013-25. doi: 10.1080/10543400903315732.
7
Sequential designs for phase I clinical trials with late-onset toxicities.具有迟发性毒性的I期临床试验的序贯设计。
Biometrics. 2000 Dec;56(4):1177-82. doi: 10.1111/j.0006-341x.2000.01177.x.
8
Continual reassessment designs with early termination.带有早期终止的连续重新评估设计
Biostatistics. 2002 Mar;3(1):87-99. doi: 10.1093/biostatistics/3.1.87.
9
Continual reassessment method for partial ordering.偏序的连续重新评估方法
Biometrics. 2011 Dec;67(4):1555-63. doi: 10.1111/j.1541-0420.2011.01560.x. Epub 2011 Mar 1.
10
Continual reassessment method: a likelihood approach.连续重新评估法：一种似然性方法。
Biometrics. 1996 Jun;52(2):673-84.
引用本文的文献
1
Phase 1 Open-Label Study of Omigapil in Patients With LAMA2- or COL6-Related Dystrophy.奥米加匹对LAMA2或COL6相关营养不良患者的1期开放标签研究。
Neurol Genet. 2024 May 29;10(3):e200148. doi: 10.1212/NXG.0000000000200148. eCollection 2024 Jun.
2
A comparison of model-free phase I dose escalation designs for dual-agent combination therapies.双药联合疗法的非模型I期剂量递增设计比较
Stat Methods Med Res. 2024 Feb;33(2):203-226. doi: 10.1177/09622802231220497. Epub 2024 Jan 24.
3
A Monte Carlo simulation study comparing the up and down, biased-coin up and down and continual reassessment methods used to estimate an effective dose (ED or ED) in anaesthesiology research.一项蒙特卡罗模拟研究，比较了用于麻醉学研究中估计有效剂量（ED或ED）的上下法、偏倚硬币上下法和连续重新评估法。
BJA Open. 2023 Sep 27;8:100225. doi: 10.1016/j.bjao.2023.100225. eCollection 2023 Dec.
4
Local continual reassessment methods for dose finding and optimization in drug-combination trials.局部连续再评估方法在药物联合试验中的剂量发现和优化。
Stat Methods Med Res. 2023 Oct;32(10):2049-2063. doi: 10.1177/09622802231192955. Epub 2023 Aug 18.
5
Comparison of design methods for a safety run-in phase of a phase II clinical trial.比较 II 期临床试验安全入组阶段的设计方法。
Clin Trials. 2023 Apr;20(2):181-191. doi: 10.1177/17407745221140913. Epub 2023 Jan 11.
6
Controlled amplification in oncology dose-finding trials.肿瘤学剂量探索试验中的控制性扩增。
Contemp Clin Trials. 2023 Feb;125:107021. doi: 10.1016/j.cct.2022.107021. Epub 2022 Dec 13.
7
Precision Bayesian phase I-II dose-finding based on utilities tailored to prognostic subgroups.基于针对预后亚组定制的效用的精准贝叶斯 I- II 期剂量发现。
Stat Med. 2021 Oct 30;40(24):5199-5217. doi: 10.1002/sim.9120. Epub 2021 Jul 9.
8
The Bayesian Design of Adaptive Clinical Trials.自适应临床试验的贝叶斯设计。
Int J Environ Res Public Health. 2021 Jan 10;18(2):530. doi: 10.3390/ijerph18020530.
9
A surface-free design for phase I dual-agent combination trials.用于I期双药联合试验的无表面设计
Stat Methods Med Res. 2020 Oct;29(10):3093-3109. doi: 10.1177/0962280220919450. Epub 2020 Apr 27.
10
Efficiency of bridging between related dose finding studies.相关剂量探索研究之间的衔接效率。
C R Math. 2013 May;351(9-10):401-404. doi: 10.1016/j.crma.2013.01.015. Epub 2013 Jun 18.
本文引用的文献
1
Stochastic approximation with virtual observations for dose-finding on discrete levels.用于离散水平剂量探索的带虚拟观测值的随机逼近法。
Biometrika. 2010 Mar;97(1):109-121. doi: 10.1093/biomet/asp065. Epub 2009 Dec 7.
2
A Bayesian dose-finding procedure for phase I clinical trials based only on the assumption of monotonicity.基于单调假设的仅用于 I 期临床试验的贝叶斯剂量探索程序。
Stat Med. 2010 Jul 30;29(17):1808-24. doi: 10.1002/sim.3963.
3
Model calibration in the continual reassessment method.序贯评估法中的模型校准
Clin Trials. 2009 Jun;6(3):227-38. doi: 10.1177/1740774509105076.
4
A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies.在I期剂量探索研究中，持续重新评估方法与标准3+3剂量递增方案的全面比较。
Clin Trials. 2008;5(5):465-77. doi: 10.1177/1740774508096474.
5
Dose-escalation designs in oncology: ADEPT and the CRM.肿瘤学中的剂量递增设计：自适应剂量递增设计（ADEPT）与连续重新评估方法（CRM）
Stat Med. 2008 Nov 20;27(26):5345-53; discussion 5354-5. doi: 10.1002/sim.3403.
6
Optimal phase I dose-escalation trial designs in oncology--a simulation study.肿瘤学中最优的I期剂量递增试验设计——一项模拟研究。
Stat Med. 2008 Nov 20;27(26):5329-44. doi: 10.1002/sim.3037.
7
Identifying the most successful dose (MSD) in dose-finding studies in cancer.在癌症剂量探索研究中确定最成功剂量（MSD）。
Pharm Stat. 2006 Jul-Sep;5(3):187-99. doi: 10.1002/pst.209.
8
Optimal designs for estimating the most successful dose.用于估计最有效剂量的最优设计。
Stat Med. 2006 Dec 30;25(24):4311-20. doi: 10.1002/sim.2685.
9
Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose control.用于癌症I期临床试验的灵活贝叶斯方法。具有过量控制的剂量递增。
Stat Med. 2005 Jul 30;24(14):2183-96. doi: 10.1002/sim.2106.
10
Continual reassessment designs with early termination.带有早期终止的连续重新评估设计
Biostatistics. 2002 Mar;3(1):87-99. doi: 10.1093/biostatistics/3.1.87.
Zotero 插件